alfacalcidol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	130	41294-56-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alfacalcidol 1alpha-Hydroxycholecalciferol alfarol alphacalcidol einsalpha alpha-calcidol 1-hydroxycholecalciferol	Molecular weight: 400.65 Formula: C27H44O2 CLOGP: 8.24 LIPINSKI: 1 HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: -5.39 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alfacalcidol
1alpha-Hydroxycholecalciferol
alfarol
alphacalcidol
einsalpha
alpha-calcidol
1-hydroxycholecalciferol

Molecular weight: 400.65
Formula: C27H44O2
CLOGP: 8.24
LIPINSKI: 1
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS: -5.39
ROTB: 6

Drug dosage:

Dose	Unit	Route
1	mcg	O
1	mcg	P
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	71 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	0.82 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	48.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1978	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasticity	476.39	14.88	191	17340	21603	63449888
Respiratory disorder	401.60	14.88	202	17329	38880	63432611
Ear pain	392.73	14.88	194	17337	35924	63435567
Body temperature increased	381.45	14.88	192	17339	37000	63434491
Night sweats	359.34	14.88	202	17329	48612	63422879
Urticaria	167.28	14.88	217	17314	165585	63305906
Lower respiratory tract infection	163.81	14.88	192	17339	132115	63339376
Hypocalcaemia	152.53	14.88	100	17431	31613	63439878
Insomnia	144.24	14.88	232	17299	215020	63256471
Back pain	129.33	14.88	248	17283	263897	63207594
Abdominal pain upper	115.01	14.88	205	17326	206239	63265252
Hypercalcaemia	109.36	14.88	78	17453	28244	63443247
Sinusitis	99.02	14.88	203	17328	226450	63245041
Hepatic function abnormal	96.79	14.88	81	17450	37061	63434430
Pruritus	92.40	14.88	263	17268	361190	63110301
Upper respiratory tract inflammation	91.20	14.88	32	17499	2491	63469000
Peripheral swelling	89.97	14.88	215	17316	265727	63205764
Osteonecrosis of jaw	88.24	14.88	75	17456	35048	63436443
Shunt stenosis	88.03	14.88	22	17509	518	63470973
Spinal compression fracture	83.55	14.88	51	17480	14232	63457259
Renal impairment	81.78	14.88	111	17420	88244	63383247
Drug ineffective	81.45	14.88	102	17429	1044663	62426828
Vomiting	69.75	14.88	322	17209	559295	62912196
Asthenia	68.62	14.88	247	17284	383357	63088134
Incorrect route of product administration	61.64	14.88	55	17476	27397	63444094
Diarrhoea	61.25	14.88	371	17160	714995	62756496
Fatigue	54.33	14.88	102	17429	887926	62583565
Drug intolerance	53.96	14.88	10	17521	308651	63162840
Joint swelling	51.08	14.88	202	17329	327464	63144027
Rash	49.23	14.88	293	17238	560578	62910913
Product dose omission issue	47	14.88	5	17526	234308	63237183
Drug hypersensitivity	44.78	14.88	15	17516	310672	63160819
Blood parathyroid hormone increased	44.28	14.88	20	17511	3018	63468473
Shunt occlusion	42.57	14.88	13	17518	652	63470839
Cerebral infarction	42.37	14.88	42	17489	23851	63447640
Interstitial lung disease	40.32	14.88	66	17465	61842	63409649
Atypical femur fracture	38.82	14.88	22	17509	5350	63466141
Enteritis infectious	34.22	14.88	15	17516	2109	63469382
Ileus	34.04	14.88	30	17501	14695	63456796
Hyperuricaemia	33.53	14.88	20	17511	5350	63466141
Iron deficiency anaemia	33.39	14.88	34	17497	19935	63451556
Abdominal discomfort	33.38	14.88	24	17507	320861	63150630
Cardiac failure	32.14	14.88	74	17457	89068	63382423
Toxoplasmosis	32.03	14.88	13	17518	1510	63469981
Alopecia	31.65	14.88	28	17503	337508	63133983
Lymph node palpable	31.05	14.88	7	17524	104	63471387
Nausea	28.78	14.88	130	17401	854341	62617150
Tetany	28.61	14.88	13	17518	1988	63469503
Large intestine polyp	28.15	14.88	21	17510	8136	63463355
Treatment failure	27.98	14.88	10	17521	199033	63272458
Anxiety	25.74	14.88	14	17517	217527	63253964
Gastroenteritis	25.48	14.88	34	17497	26556	63444935
Headache	25.13	14.88	276	17255	632965	62838526
Glossodynia	25.12	14.88	9	17522	178867	63292624
Toxicity to various agents	25.04	14.88	19	17512	247231	63224260
Anaemia	24.80	14.88	152	17379	293278	63178213
Nephrogenic anaemia	24.61	14.88	12	17519	2150	63469341
Death	24.57	14.88	41	17490	374340	63097151
Osteomyelitis	24.51	14.88	33	17498	25987	63445504
Milk-alkali syndrome	24.29	14.88	9	17522	819	63470672
Beta 2 microglobulin urine increased	23.91	14.88	5	17526	51	63471440
Arthropathy	23.83	14.88	18	17513	234774	63236717
Platelet count decreased	23.46	14.88	78	17453	116044	63355447
Therapeutic drug monitoring analysis incorrectly performed	23.20	14.88	7	17524	337	63471154
Peritonitis	23.02	14.88	26	17505	17128	63454363
Periodontitis	22.46	14.88	13	17518	3290	63468201
Hand deformity	22.42	14.88	8	17523	159449	63312042
Enterocolitis	22.26	14.88	18	17513	7840	63463651
Peripheral arterial occlusive disease	22.03	14.88	14	17517	4187	63467304
Haemodialysis complication	21.67	14.88	6	17525	212	63471279
Musculoskeletal stiffness	21.66	14.88	12	17519	184606	63286885
Rheumatoid arthritis	21.52	14.88	23	17508	253796	63217695
Chronic gastritis	21.52	14.88	12	17519	2829	63468662
Oncocytoma	21.30	14.88	4	17527	22	63471469
Immunosuppressant drug level increased	21.29	14.88	13	17518	3625	63467866
Disseminated intravascular coagulation	20.82	14.88	26	17505	19025	63452466
Calciphylaxis	20.65	14.88	12	17519	3060	63468431
Enterocolitis viral	20.43	14.88	6	17525	263	63471228
Marasmus	20.29	14.88	7	17524	518	63470973
Premature rupture of membranes	19.83	14.88	14	17517	4979	63466512
Infusion related reaction	18.93	14.88	24	17507	245497	63225994
Pneumonia aspiration	18.77	14.88	34	17497	34506	63436985
Pemphigus	18.75	14.88	14	17517	183712	63287779
Wound	18.60	14.88	11	17520	163252	63308239
Discomfort	18.07	14.88	12	17519	167362	63304129
Hyperhidrosis	17.77	14.88	4	17527	107832	63363659
Hypoalbuminaemia	17.76	14.88	19	17512	11786	63459705
Neuropsychiatric lupus	17.71	14.88	5	17526	190	63471301
Loss of personal independence in daily activities	17.30	14.88	3	17528	97287	63374204
Precocious puberty	16.94	14.88	5	17526	223	63471268
Shunt infection	16.87	14.88	4	17527	75	63471416
Colon cancer	16.84	14.88	17	17514	9861	63461630
Community acquired infection	16.76	14.88	3	17528	12	63471479
Liver disorder	16.58	14.88	42	17489	53645	63417846
Hypophosphataemia	16.51	14.88	18	17513	11408	63460083
Neurosis	16.14	14.88	5	17526	263	63471228
Muscle injury	16.06	14.88	47	17484	65298	63406193
Blood albumin decreased	15.89	14.88	20	17511	14746	63456745
Injection site pain	15.87	14.88	8	17523	129792	63341699
Autoimmune pancytopenia	15.78	14.88	4	17527	100	63471391
Oesophageal mucosal tear	15.75	14.88	3	17528	18	63471473
Feeling abnormal	15.54	14.88	11	17520	148381	63323110
Chills	15.41	14.88	6	17525	113372	63358119
Retinal haemorrhage	15.40	14.88	12	17519	4957	63466534
Hungry bone syndrome	15.34	14.88	4	17527	112	63471379
Immobilisation syndrome	15.22	14.88	5	17526	318	63471173
Pharyngitis	15.22	14.88	23	17508	20120	63451371
Hypotension	15.11	14.88	33	17498	272571	63198920

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	148.16	17.20	35	8378	747	34947771
Oesophageal perforation	119.02	17.20	32	8381	1167	34947351
Hypocalcaemia	117.42	17.20	73	8340	24216	34924302
Soft tissue mass	114.50	17.20	30	8383	989	34947529
Multimorbidity	111.97	17.20	29	8384	913	34947605
Shunt occlusion	109.34	17.20	28	8385	842	34947676
Immunosuppressant drug level increased	97.37	17.20	41	8372	6014	34942504
Superinfection	87.71	17.20	30	8383	2489	34946029
Transplant failure	81.22	17.20	31	8382	3522	34944996
Myocardial ischaemia	68.51	17.20	46	8367	17362	34931156
Inflammatory marker increased	67.58	17.20	30	8383	4998	34943520
Oesophageal carcinoma	63.53	17.20	35	8378	9269	34939249
Lung consolidation	62.81	17.20	30	8383	5906	34942612
Renal impairment	61.00	17.20	93	8320	94420	34854098
Labelled drug-drug interaction medication error	60.04	17.20	40	8373	14899	34933619
Cardiomegaly	51.82	17.20	37	8376	15401	34933117
Osteonecrosis of jaw	49.13	17.20	38	8375	17851	34930667
Rales	48.47	17.20	30	8383	9853	34938665
Hepatic function abnormal	42.70	17.20	53	8360	44310	34904208
Upper respiratory tract inflammation	42.69	17.20	16	8397	1728	34946790
Anti-erythropoietin antibody negative	42.61	17.20	10	8403	207	34948311
Procalcitonin abnormal	41.73	17.20	11	8402	371	34948147
Aplasia pure red cell	41.67	17.20	23	8390	6109	34942409
Hypercalcaemia	38.47	17.20	31	8382	15437	34933081
Drug level increased	38.22	17.20	36	8377	22060	34926458
Encephalomalacia	32.94	17.20	11	8402	847	34947671
Pleural effusion	32.59	17.20	65	8348	81481	34867037
Neuromyopathy	30.93	17.20	11	8402	1023	34947495
Drug ineffective	30.81	17.20	39	8374	456712	34491806
Calciphylaxis	30.35	17.20	11	8402	1081	34947437
Ascites	30.23	17.20	46	8367	46525	34901993
Dysphagia	28.95	17.20	53	8360	62328	34886190
Drug interaction	28.83	17.20	119	8294	225827	34722691
Lower respiratory tract infection	27.59	17.20	36	8377	31601	34916917
Fatigue	26.72	17.20	30	8383	370623	34577895
PO2 decreased	26.39	17.20	11	8402	1570	34946948
Haemoptysis	26.22	17.20	37	8376	34969	34913549
Retinopathy hypertensive	25.40	17.20	7	8406	280	34948238
PCO2 decreased	25.16	17.20	11	8402	1765	34946753
Cerebral infarction	25.13	17.20	32	8381	27423	34921095
Device related sepsis	24.94	17.20	13	8400	3080	34945438
Interstitial lung disease	24.84	17.20	51	8362	65231	34883287
Peripheral arterial occlusive disease	24.25	17.20	16	8397	5858	34942660
C-reactive protein increased	23.89	17.20	45	8368	54053	34894465
Pneumonia	22.76	17.20	157	8256	362470	34586048
Disseminated intravascular coagulation	22.49	17.20	27	8386	21789	34926729
Renal tubular acidosis	22.36	17.20	11	8402	2308	34946210
Lymphocyte count increased	21.17	17.20	12	8401	3353	34945165
Nephrotic syndrome	21.11	17.20	16	8397	7287	34941231
Acute kidney injury	20.89	17.20	135	8278	304853	34643665
Hypoglycaemia	19.97	17.20	42	8371	54598	34893920
Monocyte count increased	19.92	17.20	13	8400	4674	34943844
Hepatosplenomegaly neonatal	19.75	17.20	4	8409	40	34948478
Pyrexia	19.60	17.20	142	8271	332871	34615647
Bradycardia foetal	19.45	17.20	6	8407	358	34948160
Myeloperoxidase deficiency	19.40	17.20	4	8409	44	34948474
Extraskeletal ossification	18.86	17.20	4	8409	51	34948467
Hyperkalaemia	18.39	17.20	47	8366	69342	34879176
Immune thrombocytopenia	17.94	17.20	16	8397	9136	34939382
Low birth weight baby	17.89	17.20	15	8398	7890	34940628
Productive cough	17.37	17.20	32	8381	37781	34910737

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypocalcaemia	235.60	13.24	160	23567	49764	79670897
Shunt stenosis	224.22	13.24	57	23670	1334	79719327
Muscle spasticity	203.97	13.24	108	23619	21367	79699294
Ear pain	166.21	13.24	110	23617	32759	79687902
Respiratory disorder	152.75	13.24	118	23609	44738	79675923
Body temperature increased	145.07	13.24	114	23613	44306	79676355
Shunt occlusion	144.71	13.24	41	23686	1463	79719198
Hypercalcaemia	139.44	13.24	105	23622	38325	79682336
Night sweats	137.24	13.24	118	23609	51977	79668684
Osteonecrosis of jaw	130.62	13.24	106	23621	43120	79677541
Hepatic function abnormal	128.02	13.24	132	23595	72975	79647686
Upper respiratory tract inflammation	126.61	13.24	47	23680	3988	79716673
Renal impairment	123.00	13.24	190	23537	157593	79563068
Oesophageal perforation	112.24	13.24	34	23693	1537	79719124
Spinal compression fracture	101.17	13.24	63	23664	16895	79703766
Soft tissue mass	96.87	13.24	29	23698	1259	79719402
Multimorbidity	89.50	13.24	28	23699	1411	79719250
Drug ineffective	89.25	13.24	115	23612	1080798	78639863
Lower respiratory tract infection	83.52	13.24	143	23584	129077	79591584
Immunosuppressant drug level increased	81.75	13.24	44	23683	8983	79711678
Fatigue	68.61	13.24	107	23620	929620	78791041
Transplant failure	66.85	13.24	31	23696	4610	79716051
Blood parathyroid hormone increased	62.36	13.24	27	23700	3418	79717243
Superinfection	62.19	13.24	30	23697	4872	79715789
Interstitial lung disease	61.71	13.24	116	23611	112484	79608177
Cerebral infarction	61.71	13.24	72	23655	45604	79675057
Aplasia pure red cell	56.90	13.24	33	23694	7777	79712884
Oesophageal carcinoma	48.64	13.24	34	23693	11050	79709611
Urticaria	48.64	13.24	143	23584	185058	79535603
Myocardial ischaemia	48.14	13.24	48	23679	25471	79695190
Inflammatory marker increased	47.26	13.24	33	23694	10707	79709954
Drug intolerance	46.05	13.24	11	23716	264108	79456553
Peripheral arterial occlusive disease	45.05	13.24	29	23698	8229	79712432
Insomnia	44.45	13.24	167	23560	245003	79475658
Incorrect route of product administration	43.78	13.24	53	23674	34876	79685785
Product dose omission issue	43.77	13.24	10	23717	247527	79473134
Labelled drug-drug interaction medication error	43.17	13.24	47	23680	27603	79693058
Lung consolidation	42.93	13.24	29	23698	8918	79711743
Disseminated intravascular coagulation	42.68	13.24	53	23674	35789	79684872
Platelet count decreased	42.51	13.24	141	23586	194523	79526138
Drug hypersensitivity	40.72	13.24	19	23708	298897	79421764
Hyperuricaemia	40.05	13.24	31	23696	11768	79708893
Procalcitonin abnormal	39.19	13.24	11	23716	379	79720282
Anti-erythropoietin antibody negative	36.31	13.24	10	23717	321	79720340
Anaemia	36.00	13.24	241	23486	444774	79275887
Back pain	35.83	13.24	182	23545	303998	79416663
Gastroenteritis	33.72	13.24	46	23681	34036	79686625
Completed suicide	32.88	13.24	16	23711	245751	79474910
Diarrhoea	32.53	13.24	402	23325	880087	78840574
Enteritis infectious	32.28	13.24	17	23710	3321	79717340
Hyperhidrosis	31.42	13.24	4	23723	151488	79569173
Calciphylaxis	30.34	13.24	17	23710	3753	79716908
Cardiac failure	30.16	13.24	108	23619	154734	79565927
Periodontitis	30.13	13.24	18	23709	4478	79716183
Large intestine polyp	29.87	13.24	27	23700	12681	79707980
Cardiomegaly	29.83	13.24	38	23689	26314	79694347
Tetany	29.57	13.24	15	23712	2713	79717948
Abdominal pain upper	28.53	13.24	137	23590	223682	79496979
Atypical femur fracture	27.76	13.24	18	23709	5171	79715490
Pruritus	27.38	13.24	206	23521	394442	79326219
Lymph node palpable	27.32	13.24	7	23720	169	79720492
Encephalomalacia	26.71	13.24	11	23716	1230	79719431
Chronic gastritis	26.52	13.24	16	23711	4052	79716609
Nausea	26.33	13.24	172	23555	957024	78763637
Hungry bone syndrome	26.30	13.24	7	23720	197	79720464
Pneumonia aspiration	26.10	13.24	60	23667	66907	79653754
Iron deficiency anaemia	25.93	13.24	35	23692	25637	79695024
Anxiety	25.33	13.24	22	23705	248490	79472171
Nephrotic syndrome	24.82	13.24	23	23704	11151	79709510
Treatment failure	24.52	13.24	10	23717	170476	79550185
Rales	24.49	13.24	30	23697	19971	79700690
Neuromyopathy	24.30	13.24	11	23716	1547	79719114
Liver disorder	24.06	13.24	61	23666	72356	79648305
Toxoplasmosis	24.01	13.24	13	23714	2684	79717977
Ileus	23.88	13.24	34	23693	26177	79694484
Beta 2 microglobulin urine increased	23.65	13.24	6	23721	139	79720522
Peritonitis	23.55	13.24	35	23692	28001	79692660
Hypophosphataemia	22.99	13.24	29	23698	19884	79700777
Haemoptysis	22.74	13.24	51	23676	55948	79664713
Ascites	22.40	13.24	61	23666	75501	79645160
Sinusitis	22.31	13.24	116	23611	195385	79525276
Pyrexia	22.10	13.24	303	23424	678406	79042255
Osteomyelitis	22.03	13.24	37	23690	32828	79687833
Enterocolitis viral	21.76	13.24	7	23720	386	79720275
Enterocolitis	21.49	13.24	24	23703	14488	79706173
Premature rupture of membranes	21.48	13.24	14	23713	4055	79716606
Retinopathy hypertensive	20.01	13.24	7	23720	500	79720161
Rash	19.97	13.24	261	23466	578097	79142564
Vomiting	19.97	13.24	293	23434	665535	79055126
Oncocytoma	19.93	13.24	4	23723	30	79720631
Concomitant disease aggravated	19.89	13.24	22	23705	13145	79707516
Injection site pain	19.70	13.24	7	23720	129831	79590830
Immobilisation syndrome	19.61	13.24	7	23720	531	79720130
Nephrogenic anaemia	19.57	13.24	13	23714	3889	79716772
Abdominal discomfort	19.21	13.24	28	23699	250699	79469962
Hypoglycaemia	19.04	13.24	70	23657	101524	79619137
Milk-alkali syndrome	18.95	13.24	9	23718	1411	79719250
Haemodialysis complication	18.92	13.24	6	23721	316	79720345
Pharyngitis	18.89	13.24	28	23699	22347	79698314
Death	18.63	13.24	96	23631	566418	79154243
Pleural effusion	18.55	13.24	89	23638	145173	79575488
Musculoskeletal stiffness	18.43	13.24	15	23712	174993	79545668
Marasmus	18.42	13.24	8	23719	1020	79719641
Renal tubular acidosis	18.03	13.24	12	23715	3602	79717059
Decreased appetite	18.00	13.24	168	23559	342250	79378411
Hyperphosphataemia	17.92	13.24	15	23712	6361	79714300
Premature delivery	17.88	13.24	28	23699	23439	79697222
Hypotension	17.85	13.24	69	23658	440248	79280413
Therapeutic drug monitoring analysis incorrectly performed	17.66	13.24	7	23720	709	79719952
PO2 decreased	17.65	13.24	11	23716	2952	79717709
Immune thrombocytopenia	17.56	13.24	24	23703	17781	79702880
Hyperkalaemia	17.54	13.24	74	23653	114324	79606337
Infusion related reaction	17.35	13.24	26	23701	230211	79490450
Intentional overdose	17.34	13.24	5	23722	105955	79614706
Neuropsychiatric lupus	17.29	13.24	5	23722	192	79720469
Haemorrhage subcutaneous	17.12	13.24	13	23714	4796	79715865
Drug level increased	17.10	13.24	37	23690	39614	79681047
PCO2 decreased	17.02	13.24	11	23716	3143	79717518
Shunt infection	16.93	13.24	5	23722	207	79720454
Pain in extremity	16.87	13.24	54	23673	364484	79356177
Depression	16.81	13.24	24	23703	216766	79503895
Calcium metabolism disorder	16.78	13.24	4	23723	71	79720590
Colon cancer	16.53	13.24	21	23706	14502	79706159
Loss of personal independence in daily activities	16.49	13.24	5	23722	102575	79618086
Pneumonia	16.19	13.24	281	23446	659965	79060696
Hyperparathyroidism secondary	16.16	13.24	10	23717	2650	79718011
Pneumonia bacterial	16.04	13.24	24	23703	19307	79701354
Oesophageal mucosal tear	15.83	13.24	3	23724	16	79720645
Skin erosion	15.79	13.24	12	23715	4433	79716228
Shunt malfunction	15.72	13.24	5	23722	266	79720395
Acute kidney injury	15.72	13.24	229	23498	519175	79201486
Femoral neck fracture	15.63	13.24	17	23710	9967	79710694
Sepsis	15.59	13.24	135	23592	269293	79451368
Cholangitis	15.38	13.24	19	23708	12757	79707904
Eczema asteatotic	15.21	13.24	6	23721	600	79720061
Feeling abnormal	15.14	13.24	15	23712	159184	79561477
Disease progression	14.70	13.24	20	23707	184342	79536319
Precocious puberty	14.68	13.24	5	23722	330	79720331
Community acquired infection	14.46	13.24	3	23724	27	79720634
Femur fracture	14.37	13.24	34	23693	38618	79682043
Calculus urinary	14.32	13.24	9	23718	2451	79718210
Thalamus haemorrhage	14.24	13.24	8	23719	1774	79718887
Aortic dissection	14.24	13.24	11	23716	4164	79716497
Device related sepsis	14.16	13.24	13	23714	6227	79714434
Pemphigoid	14.14	13.24	20	23707	15295	79705366
Idiopathic pulmonary fibrosis	14.11	13.24	11	23716	4217	79716444
Chronic obstructive pulmonary disease	14.03	13.24	4	23723	85415	79635246
Alopecia	13.95	13.24	30	23697	231325	79489336
Myeloperoxidase deficiency	13.92	13.24	3	23724	33	79720628
Memory impairment	13.86	13.24	8	23719	111726	79608935
Protein urine present	13.75	13.24	16	23711	10096	79710565
Suicidal ideation	13.65	13.24	3	23724	76337	79644324
Suicide attempt	13.41	13.24	4	23723	82928	79637733
Stag horn calculus	13.40	13.24	4	23723	172	79720489
Shunt aneurysm	13.39	13.24	3	23724	40	79720621
Neurosis	13.38	13.24	5	23722	432	79720229
Arthropathy	13.34	13.24	20	23707	177091	79543570

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A11CC03	ALIMENTARY TRACT AND METABOLISM VITAMINS VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO Vitamin D and analogues
ATC	M05BB06	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates, combinations
MeSH PA	D050071	Bone Density Conservation Agents
CHEBI has role	CHEBI:50646	antiosteoporotic

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal osteodystrophy	indication	16726004	DOID:13068
Hypoparathyroidism	indication	36976004	DOID:11199
Hyperparathyroidism	indication	66999008	DOID:13543
Neonatal hypocalcemia	indication	268846006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST				WOMBAT-PK	KEGG DRUG
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6		DRUG MATRIX

External reference:

ID	Source
D01518	KEGG_DRUG
12062	RXNORM
C0044410	UMLSCUI
CHEBI:31186	CHEBI
M9B	PDB_CHEM_ID
CHEMBL1601669	ChEMBL_ID
DB01436	DRUGBANK_ID
C008088	MESH_SUPPLEMENTAL_RECORD_UI
5282181	PUBCHEM_CID
4489	INN_ID
URQ2517572	UNII
11984007	SNOMEDCT_US
329325000	SNOMEDCT_US
003501	NDDF

Pharmaceutical products:

None